Affiliation:
1. Division of Transfusion Medicine, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD;
2. Division of Hematology/Oncology, Simmons Cancer Institute, Southern Illinois University School of Medicine, Springfield, IL; and
3. New York Blood Center, New York, NY
Abstract
Abstract
Blood transfusions are life-saving therapies; however, they can result in adverse events that can be infectious or, more commonly, noninfectious. The most common noninfectious reactions include febrile nonhemolytic transfusion reactions, allergic transfusion reactions, transfusion-associated circulatory overload, transfusion-related acute lung injury, and acute and delayed hemolytic transfusion reactions. These reactions can be asymptomatic, mild, or potentially fatal. There are several new methodologies to diagnose, treat, and prevent these reactions. Hemovigilance systems for monitoring transfusion events have been developed and demonstrated decreases in some adverse events, such as hemolytic transfusion reactions. Now vein-to-vein databases are being created to study the interactions of the donor, product, and patient factors in the role of adverse outcomes. This article reviews the definition, pathophysiology, management, and mitigation strategies, including the role of the donor, product, and patient, of the most common noninfectious transfusion-associated adverse events. Prevention strategies, such as leukoreduction, plasma reduction, additive solutions, and patient blood management programs, are actively being used to enhance transfusion safety. Understanding the incidence, pathophysiology, and current management strategies will help to create innovative products and continually hone in on best transfusion practices that suit individualized patient needs.
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry
Reference80 articles.
1. Pfuntner
A
, WierLM, StocksC. Most frequent procedures performed in U.S. Hospitals, 2011. Available at: https://www.hcup-us.ahrq.gov/reports/statbriefs/sb165.jsp. Accessed 9 November 2018.
2. Donor testing and risk: current prevalence, incidence, and residual risk of transfusion-transmissible agents in US allogeneic donations;Zou;Transfus Med Rev,2012
3. Supplemental findings from the National Blood Collection and Utilization Surveys, 2013 and 2015;Sapiano;Transfusion,2017
4. Transfusion-associated circulatory overload and transfusion-related acute lung injury;Semple;Blood,2019
5. Fatalities Reported to FDA Following Blood Collection and Transfusion Annual Summary for FY2016. Available at: https://www.fda.gov/downloads/BiologicsBloodVaccines/SafetyAvailability/ReportaProblem/TransfusionDonationFatalities/UCM598243.pdf. Accessed 9 November 2018.
Cited by
96 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献